SFEBES2025 Poster Presentations Reproductive Endocrinology (22 abstracts)
Prevalence of cardiometabolic risk in polycystic ovary syndrome (PCOS): insights from an interim analysis of the DAISy-PCOS cohort
Tara McDonnell 1 , Eka Melson 2,3 , Meryem Ertugrul 2,3 , Thais P. Rocha 4 , Leanne Cussen 1 , Cara Go 5 , Fannie Lajeunesse-Trempe 6 , Punith Kempegowda 4,7 , Merah Al-Busaidy 1 , Thozhukat Sathyapalan 8 , Jyotsna Pundir 9 , Richard Anderson 10 , Barbara McGowan 11 , D. Aled Rees 12 , Georgios K. Dimitriadis 6 , Harpal S. Randeva 13 , Channa N. Jayasena 3,5 , Alice J. Sitch 4 , Michael W. O’Reilly 1 , Wiebke Arlt 2,3 & for the DAISy-PCOS Investigators 3
1Royal College of Surgeons in Ireland, Dublin, Ireland; 2MRC Laboratory of Medical Sciences, London, United Kingdom; 3Imperial College London, London, United Kingdom; 4University of Birmingham, Birmingham, United Kingdom; 5Imperial College Healthcare NHS Trust, London, United Kingdom; 6King’s College Hospital NHS Foundation Trust, London, United Kingdom; 7University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; 8Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom; 9Barts Health NHS Trust, London, United Kingdom; 10University of Edinburgh, Edinburgh, United Kingdom; 11Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 12Cardiff University, Cardiff, United Kingdom; 13University of Warwick, Coventry, United Kingdom
Introduction: PCOS affects at least 10% of women and is associated with an increased cardiometabolic risk and higher prevalence of hypertension, hyperlipidaemia, insulin resistance and type 2 diabetes in population-based studies. The metabolic burden of PCOS traverses the lifespan of women with PCOS. We describe the metabolic characteristics of the UK-wide prospective multi-centre DAISy-PCOS dcohort.
Methods: We prospectively recruited 726 treatment-naïve women with PCOS in the UK and Ireland. All fulfilled the Rotterdam criteria for diagnosis; median age was 30 (IQR: 26-34) years, body mass index (BMI) 31.1 (25.1-38.4) kg/m², 23.3% had non-white ethnicity]. Participants underwent standardised assessments including body composition analysis, fasting bloods and oral glucose tolerance test (OGTT) with insulin and glucose measurements at 0, 30, 60, 90 and 120 minutes after 75g glucose load. Metabolic syndrome was defined using the Adult Treatment Panel (ATP) III criteria. Dysglycaemia included those with diabetes (fasting glucose ≥ 7.0mmol, 2hOGTT glucose ≥11.1, Hba1c ≥48mmol/mol) or a diagnosis of prediabetes defined by the American Diabetes Association (ADA) criteria. The ADA defines prediabetes as impaired fasting glucose between 5.6 and 7mmol/l and HbA1c >38mmol/mol.
Results: At least one criteria for dysglycaemia was present in 25% [n=166/654] of participants with available glucose parameters (IFG [n=68/662], impaired glucose tolerance (IFG) [n=67/654], HbA1c >38mmol/mol [n=102/654]). Type 2 diabetes was diagnosed in 2.6% [n=17/654] of participants. A pre-existing diagnosis of hypertension and dyslipidaemia was self-reported by 4.4% [n=32] and 6.9% [n=50] respectively. Following phenotyping 18.4% had blood pressure measurements greater than 130/85mmHg, 45.5% had evidence of dyslipidaemia and 63% of participants had a waist circumference exceeding 88 cm. Overall, the prevalence of metabolic syndrome in this cohort was 16.9%.
Conclusion: Our analysis demonstrates a high prevalence of cardiometabolic risk factors present in this prospectively recruited cohort of young women with PCOS.
Volume 109
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more